Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
نویسندگان
چکیده
منابع مشابه
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
A doublet chemotherapy, generally cisplatin or carboplatinbased, is the standard of care in the management of advanced non-small cell lung cancer (NSCLC) patients, defined as unresectable stage IIIB or stage IV disease [1]. Numerous trials have established the superiority of third generation cytotoxic agent combinations over old fashion regimens (2–4). In one of these studies published by Bonom...
متن کامل[Second-line chemotherapy in non-small cell lung cancer].
The progress in first-line chemotherapy in non-small cell lung cancer with efficient and often well-tolerated combinations has progressively led to the proposal of second-line chemotherapy for the patients. Docetaxel provides significantly enhanced survival compared with palliative treatments. Various phase II studies with vinorelbine, gemcitabine and paclitaxel have been reported. Pemetrexed h...
متن کاملOutcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution
BACKGROUND This study analyzed the negative prognostic factors in patients who received second-line chemotherapy for advanced inoperable non-small cell lung cancer (NSCLC). METHODS We retrospectively reviewed the records of 137 patients with inoperable stage III-IV NSCLC who received second-line chemotherapy. The effects of clinical parameters on survival were analyzed and the hazard ratios (...
متن کاملGemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.
Aim of this study was to estimate efficacy of gemcitabine in first and the second-line chemotherapy for patients with advanced non-small cell lung cancer (stage III and IV). In first-line chemotherapy, 120 patients were treated with different chemotherapy regimens. Fifty-nine patients were treated with gemcitabine / cisplatin (PG), 41 with cisplatin / etoposide (PE) and 20 with mitomycin / ifos...
متن کاملWeekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial.
BACKGROUND Open-label, single-centre Phase II trial evaluating the toxicity and antitumour activity of weekly docetaxel in the second-line management of advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Treatment comprised docetaxel 35 mg/m2 weekly for 6 weeks followed by 2 weeks' rest for a maximum of 3 cycles. RESULTS Thirty-six patients received 220 weekly doses of doceta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2005
ISSN: 0923-7534
DOI: 10.1093/annonc/mdi231